Total Parenteral Nutrition-induced Cholestasis Clinical Trial
Official title:
Use of a Fish Oil-Based Intravenous Lipid Emulsion (Omegaven®) in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury
The purpose of this study is to determine whether the omega-3 fatty acid emulsion (Omegaven®), when used in place of the conventional soy-based fat emulsion (Intralipid), is effective in treating parenteral nutrition associated liver disease (PNALD) in children. The study hypothesis is that Omegaven® can be safely provided to children who are dependent on parenteral nutrition and have PNALD, and can reverse or prevent progression of PNALD until the child can take adequate nutrition by mouth.
Rationale for Omegaven® Treatment Unlike conventional intravenous fat emulsions, Omegaven® is comprised solely of fish oils containing primarily omega-3 fatty acids. Animal studies have shown that IV lipid emulsions such as fish oil that are high in eicosapentaenic and docosahexaenoic acid reduce impairment of bile flow as seen in cholestasis caused by conventional fat emulsions(1,2). By administering Omegaven® in place of conventional phytosterol/soybean fat emulsions, the cholestasis may be reversed and patients will be able to be maintained on adequate PN until they are able to ingest adequate nutrition enterally. References 1. Chen W. Effects of fat emulsions with different fatty acid composition on plasma and hepatic lipids in rats receiving total parenteral nutrition. Clinical Nutrition 1996;15:24. 2. Yeh S. Effects of fish oil and safflower oil emulsions on diet-induced hepatic steatosis in rats receiving total parenteral nutrition. Clinical Nutrition 1996;15:80. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02370251 -
Compassionate Use of Omegaven in Children
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT01323907 -
Compassionate Use of Omegaven IV Fat Emulsion
|
N/A | |
| Recruiting |
NCT01565278 -
Fish Oil for Patients With Liver Disease Due to Parenteral Nutrition
|
Phase 3 | |
| Terminated |
NCT00816348 -
Compassionate Use of Omegaven IV Fat Emulsion
|
Phase 2 | |
| Completed |
NCT02534077 -
Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants
|
Phase 3 | |
| Approved for marketing |
NCT02780193 -
Intravenous Fish Oils in the Treatment of Parenteral Nutrition Liver Injury
|
||
| Approved for marketing |
NCT02929303 -
Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD
|
||
| Approved for marketing |
NCT02328768 -
Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children
|
||
| Approved for marketing |
NCT01412359 -
Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Associated Hepatic Injury
|